Lipiflow Objectively Improves Dry Eye Signs and Symptoms: Control Eye (no Lipiflow) versus Case Eye (Lipiflow used)
The below study assess the safety and effectiveness of a 12-minute LipiFlow monocular treatment on elderly Chinese patients with MGD. Previous studies reported that a single LipiFlow 12-minute treatment improved meibomian gland secretion, Tear Break Up Time (TBUT) which is a measure of instability of the tear film to keep the tear on the surface and not dry up too quickly, and symptom scores at one month, nine months, 12 months, and even three years posttreatment compared with traditional or new-style warm compress therapies and common clinical methods of physical expression of meibomian gland obstruction (See Reference1).
Most studies have shown the efficacy of LipiFlow by treatment of both eyes but this is the first study to report the results of monocular treatment with LipiFlow with the contralateral eye as a control (one eye had Lipiflow & the other did not)
They used clinical parameters that show LipiFlow significantly improves of meibomian gland function and tear film stability in the test eye.
They show that LipiFlow restored the function of previously blocked dysfunctional meibomian glands and an increase in gland function improved tear film stability, which may directly influence other objective and subjective measures of ocular surface health: TBUT improved, reduced corneal staining (all MDs want to decrease corneal staining as corneal staining can lead to permanent corneal scarring and it can make the cornea more likely to get a bacterial infection as the first layer of the cornea’s defense, the epithelium, is broken down or gone), and improved subjective symptoms provide strong evidence of the efficiency of LipiFlow.
Sandra Lora Cremers, MD, FACS
J Ophthalmol. 2016;2016:9640643. doi: 10.1155/2016/9640643. Epub 2016 Dec 27.